Clinical trials: Immunogenicity
COVID-19
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart…
- Trial name
- COVID-19 (NCT05468736)
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- Where
- 94 sites in United States, Colombia and 8 more
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups
The purpose of this study is to assess the safety and tolerability of, and the immune response to a non-adjuvanted H5N1 influenza vaccine in an adult and elderly population and in specified risk groups.
- Trial name
- NCT00711295
- Testing
- H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
- Where
- 45 sites in Austria, Belgium and 5 more
- Volunteers
- 3,583 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
The aim of the study is to evaluate the safety and immunogenicity of the 2011-2012 formulation of Fluzone and Fluzone High-Dose vaccines in participants aged 65 years and older.
- Trial name
- NCT01430819
- Testing
- Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
- Where
- 6 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults
Phase I/II study to determine safety, tolerance and immunogenicity of EuCorVac-19, a recombinant protein vaccine, for the prevention of COVID-19 in healthy adults
- Trial name
- NCT04783311
- Testing
- EuCorVac-19, Normal Saline
- Where
- South Korea
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Rubella, Measles
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \&…
- Conditions
- Rubella, Measles, Mumps
- Trial name
- NCT01702428
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 90 sites in United States, Estonia and 4 more
- Volunteers
- 5,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting…
- Trial name
- NCT04480463
- Testing
- SCD411, Aflibercept
- Where
- 130 sites in United States, Australia and 12 more
- Volunteers
- 576 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)
This study is designed 1) to evaluate the safety, tolerability, and immunogenicity of V114 and Prevnar 13™, 2) to describe the safety of sequential administration of V114 or Prevnar 13™ followed by PNEUMOVAX™23, and 3) to…
- Trial name
- PNEU-PATH (NCT03480763)
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 22 sites in United States, South Korea and 2 more
- Volunteers
- 652 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Clostridium Difficile Associated Disease
A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
This study will investigate a Clostridium difficile vaccine in healthy adults aged 65-85 years. Each subject will initially receive 3 doses of vaccine on 1 of 2 vaccination schedules.
- Trial name
- NCT02561195
- Testing
- Clostridium difficile Vaccine
- Where
- 17 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study.
- Trial name
- NCT02658409
- Testing
- GC3106(quadrivalent cell-culture based influenza vaccine), Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)
- Where
- South Korea
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Healthy Volunteers
A Study of LAD106 in Healthy Adult Participants
The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in…
- Trial name
- NCT07471932
- Testing
- LAD106, Lebrikizumab
- Where
- Netherlands
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Almirall, S.A.
Herpes Zoster
Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine
This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers.
- Trial name
- NCT05718037
- Testing
- Recombinant Zoster Vaccine, Zoster Vaccine Recombinant, Adjuvanted
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD), Healthy Participants
A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
This study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple doses of RO7830698 in healthy participants and participants with chronic obstructive…
- Trial name
- NCT07822334
- Testing
- RO7830698
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Influenza
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
Flublok was studied previously in children 6 -59 months of age and demonstrated less than satisfactory immunogenicity results, especially in the 6-36 month age group.
- Trial name
- NCT01959945
- Testing
- Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Diarrhea
Prevention of Diarrheal Disease Due to Infection With Enterotoxigenic E. Coli (ETEC)
This is a Phase II b, double-blind, randomized, placebo-controlled study in healthy adults (age 18-65 years) to evaluate the safety, immunogenicity, different diagnostic tools and efficacy of ETVAX.
- Trial name
- NCT03729219
- Testing
- E. coli ETVAX
- Where
- Finland
- Volunteers
- 749 people, healthy volunteers welcome
- Sponsor
- Scandinavian Biopharma AB
Healthy
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
- Trial name
- NCT01005407
- Testing
- Engerix-B
- Where
- 32 sites in United States, Canada
- Volunteers
- 2,452 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Infections, Streptococcal
Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of a booster (fourth) dose of pneumococcal vaccine GSK1024850A when co-administered with Hiberix at 12-18 months of age, in children primed…
- Trial name
- NCT00911144
- Testing
- GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A), Wyeth-Lederle's Prevenar™, GSK Biologicals' Hiberix™
- Where
- 14 sites in South Korea
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis A Vaccine
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine
The purpose of this study is to evaluate the immunogenicity and safety after one primary dose and one additional dose of inactivated hepatitis A vaccine are administered in Korean healthy children aged 12-23 months.
- Trial name
- VITHA-C (NCT03654664)
- Testing
- Inactivated hepatitis A vaccine, Havrix Inj
- Where
- 10 sites in South Korea
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Influenza
A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults
Recombinant hemagglutinin has been shown to induce protective neutralising antibodies against avian influenza virus but is relatively non-immunogenic.
- Trial name
- FLU003 (NCT02335164)
- Testing
- recombinant influenza hemagglutinin, Advax1, Advax2
- Where
- Australia
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
This study will compare the safety and tolerability of lyophilized BNT162b2 presented in single dose vials to those of frozen-liquid BNT162b2 in multidose vials and determine whether the immune response is noninferior.
- Trial name
- NCT04816669
- Testing
- BNT162b2
- Where
- 21 sites in United States
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- BioNTech SE